U.S. flag An official website of the United States government
  1. Home
  2. Science & Research
  3. About Science & Research at FDA
  4. FDA Webinar Series on Alternative Methods: Showcasing cutting-edge technologies for disease modeling, efficacy, and safety
  1. About Science & Research at FDA

FDA Webinar Series on Alternative Methods: Showcasing cutting-edge technologies for disease modeling, efficacy, and safety

Image
Microphone on podium before webinar audience
Caption
Promoting cutting-edge technologies for disease modeling, efficacy, and safety

FDA’s Office of the Chief Scientist is launching a webinar series on Alternative Methods as part of FDA’s commitment to promote novel technologies and potentially incorporate them into its regulatory review, as applicable.  

An Opportunity for Developers and FDA Scientists

Continuing education in new predictive in vitro, in vivo, and in silico methods is vital to ensuring that FDA regulators and researchers have a broad skill set and remain current with cutting-edge science and technology. To that end, FDA’s Alternative Methods Webinar Series will give developers the opportunity to present their new methods and methodologies exclusively to FDA scientists.

How to be Considered for Selection

To be considered for selection, please submit the following information to FDA at:

Alternatives@fda.hhs.gov

  1. A description of your new method or methodology, including origin of cells (if appropriate), species of animal (if appropriate), etc.
  2. A description of the proposed context of use of your new method or methodology.
  3. A description of the regulatory issue/gap where it could have an impact on an important regulatory issue.
  4. Data from use of your method, including any publications.

 

Your participation in this webinar would mean that your new technology would be introduced to FDA and that individual FDA programs would have the option to contact you for further information.  However, your participation in FDA’s webinar series would not constitute FDA’s endorsement of your new method or methodology.   Nor would it mean that FDA would assist you in qualifying your new method for regulatory use.  

FDA will respond within 60 days to your webinar submission, with either a request for more information, a potential time for your webinar, or a reason why your new technology might not qualify for this program.  Although every new technology is exciting to FDA, it may not be mature enough to be incorporated into this program at this time.

This new webinar series joins ongoing FDA initiatives to bring the latest innovative technology to its regulatory and research scientists. 

Resources for You

Advancing Alternative Methods at FDA

FDA's Predictive Toxicology Roadmap